These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18923820)

  • 1. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
    Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA
    Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
    Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
    Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous vasopressin, innate anxiety, and the emission of pro-social 50-kHz ultrasonic vocalizations during social play behavior in juvenile rats.
    Lukas M; Wöhr M
    Psychoneuroendocrinology; 2015 Jun; 56():35-44. PubMed ID: 25800147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
    Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
    J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
    Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
    Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
    Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxytocin and vasopressin modulation of social anxiety following adolescent intermittent ethanol exposure.
    Dannenhoffer CA; Kim EU; Saalfield J; Werner DF; Varlinskaya EI; Spear LP
    Psychopharmacology (Berl); 2018 Oct; 235(10):3065-3077. PubMed ID: 30141056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice.
    Bielsky IF; Hu SB; Szegda KL; Westphal H; Young LJ
    Neuropsychopharmacology; 2004 Mar; 29(3):483-93. PubMed ID: 14647484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contributions of vasopressin V1A and oxytocin receptors in the amygdala to pain-related behaviors in rats.
    Cragg B; Ji G; Neugebauer V
    Mol Pain; 2016; 12():. PubMed ID: 27837170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
    Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
    J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
    Serradeil-Le Gal C
    Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
    Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
    Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin V1a and V1b receptors: from molecules to physiological systems.
    Koshimizu TA; Nakamura K; Egashira N; Hiroyama M; Nonoguchi H; Tanoue A
    Physiol Rev; 2012 Oct; 92(4):1813-64. PubMed ID: 23073632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
    Chan WY; Wo NC; Manning M
    Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.